Your shopping cart is currently empty

Sameridine (NIH-10908) acts as a weak partial agonist at the μ-opioid receptor. When administered intrathecally, it induces local anesthesia and analgesia. At low doses, Sameridine minimally affects respiratory function, but higher doses can suppress respiratory response. It is useful for research into analgesic effects.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | Sameridine (NIH-10908) acts as a weak partial agonist at the μ-opioid receptor. When administered intrathecally, it induces local anesthesia and analgesia. At low doses, Sameridine minimally affects respiratory function, but higher doses can suppress respiratory response. It is useful for research into analgesic effects. |
| In vivo | Intrathecal administration of Sameridine (5-10 mg/mL (10 μL), twice daily, five days a week, for two weeks) did not induce noticeable neurotoxicity in a rat model. |
| Synonyms | NIH 10908 free base |
| Molecular Weight | 330.52 |
| Formula | C21H34N2O |
| Cas No. | 143257-97-0 |
| Smiles | O=C(N(C)CC)C1(C=2C=CC=CC2)CCN(CCCCCC)CC1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.